Alphatec Stock Gets Weaker EPS Forecast from HC Wainwright

Alphatec Holdings, Inc. (NASDAQ:ATEC – Free Report) – Equities research analysts at HC Wainwright reduced their Q1 2027 earnings per share (EPS) estimates for Alphatec in a report issued on Friday, November 13th. HC Wainwright analyst S. Lee now forecasts that the medical technology company will post earnings of $0.03 per share for the quarter, down from their prior forecast of $0.08. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Alphatec’s current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Alphatec’s Q2 2027 earnings at $0.07 EPS, Q3 2027 earnings at $0.07 EPS and Q4 2027 earnings at $0.15 EPS.

Other equities analysts have also recently issued reports about the stock. Stephens started coverage on shares of Alphatec in a research report on Thursday, July 23rd. They set an “overweight” rating and a $15.00 price objective for the company. Wall Street Zen downgraded shares of Alphatec from a “buy” rating to a “hold” rating in a report on Sunday, October 11th. TD Cowen cut their target price on shares of Alphatec from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, October 30th. Canaccord Genuity Group reduced their price target on shares of Alphatec from $19.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, October 30th. Finally, UBS Group lowered shares of Alphatec from a “buy” rating to a “neutral” rating and decreased their price target for the company from $15.00 to $8.50 in a research note on Wednesday, November 4th. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.37.

Read Our Latest Stock Report on ATEC

Alphatec Price Performance

Alphatec stock opened at $6.78 on Tuesday. The company’s fifty day moving average price is $9.70 and its 200 day moving average price is $10.12. Alphatec has a 1 year low of $6.72 and a 1 year high of $23.29.

Alphatec (NASDAQ:ATEC – Get Free Report) last announced its earnings results on Thursday, October 29th. The medical technology company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Alphatec had a negative net margin of 10.35% and a negative return on equity of 6,752.24%. The business had revenue of $221.17 million for the quarter, compared to analysts’ expectations of $225.16 million. During the same quarter last year, the business earned $0.03 EPS. The company’s quarterly revenue was up 12.6% on a year-over-year basis.

Institutional Investors Weigh In On Alphatec

A number of large investors have recently modified their holdings of ATEC. Sterling Capital Management LLC raised its position in shares of Alphatec by 841.5% in the third quarter. Sterling Capital Management LLC now owns 4,105 shares of the medical technology company’s stock valued at $42,000 after buying an additional 3,669 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of Alphatec in the second quarter worth about $52,000. Allworth Financial LP boosted its position in Alphatec by 82.6% during the second quarter. Allworth Financial LP now owns 6,666 shares of the medical technology company’s stock worth $58,000 after acquiring an additional 3,015 shares during the last quarter. Chicago Partners Investment Group LLC acquired a new position in Alphatec during the third quarter worth about $112,000. Finally, Lido Advisors LLC acquired a new position in Alphatec during the first quarter worth about $115,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Insider Activity at Alphatec

In other news, CEO Patrick Miles purchased 115,000 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was purchased at an average cost of $8.81 per share, for a total transaction of $1,013,150.00. Following the completion of the transaction, the chief executive officer owned 5,893,551 shares of the company’s stock, valued at $51,922,184.31. This trade represents a 1.99% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David Demski acquired 60,000 shares of Alphatec stock in a transaction that occurred on Friday, October 30th. The stock was purchased at an average cost of $6.81 per share, with a total value of $408,600.00. Following the completion of the purchase, the director owned 491,635 shares in the company, valued at $3,348,034.35. The trade was a 13.90% increase in their position. The SEC filing for this purchase provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.48% of the stock is currently owned by insiders.

About Alphatec

(Get Free Report)

Alphatec Holdings, Inc. is a medical technology company focused on developing and marketing products for spine surgery. Its offerings are intended to support the surgical treatment of spinal disorders and include implants, biologics, instruments and access systems, along with technologies designed to assist surgeons during procedures. The company’s product portfolio includes solutions for several surgical approaches and stages of spine care, including systems for planning, accessing and instrumenting the spine.

Recommended Stories

Earnings History and Estimates for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.